Inovio Pharmaceuticals Inc

Inovio’s insider buying spree signals strong confidence in its DNA‑vaccine pipeline—learn how CEO moves, Akeso partnership, and future milestones could boost value.

Inovio’s February 2026 insider trades reveal a strategic shift: executives balance liquidity with confidence in its DNA‑based vaccine pipeline, highlighting market access, pricing, and partnership challenges amid growing competition.